Imaging of Tumor Viability in Lung Cancer: Initial Results Using 23Na-MRI
Imaging of Tumor Viability in Lung Cancer: Initial Results Using 23Na-MRI
复制标题
DOI：
10.1055/s-0031-1299277
复制
发表时间：
2012-04-01
影响因子：
1.8
通讯作者：
Fink, C.
中科院分区：
文献类型：
--
作者：
Henzler, T.;Konstandin, S.;Fink, C.
目的：Na-23-MRI 已被提议作为一种潜在的成像生物标志物，用于评估肿瘤活力和评估治疗反应，但尚未在肺癌患者中进行评估。我们的目的是评估 Na-23-MRI 在肺癌患者中的可行性。材料和方法：使用临床 3 Tesla MRI 系统（Magnetom TimTrio，Siemens Healthcare，埃尔兰根，德国）对三名 IV 期肺腺癌患者进行了检查。通过Na-23-MRI与H-1-MR、CT和FDG-PET-CT图像的比较和融合，证明了Na-23-MRI图像的可行性。测量肿瘤和椎管脑脊液(CSF)的Na-23信号强度(SI)，并计算肿瘤和CSF的SI比率。对一名化疗患者在开始联合治疗（卡铂、吉西他滨、西妥昔单抗）前后进行了检查。结果：所有 Na-23-MRI 检查均成功完成，且具有诊断质量。 Na-23-MRI 图像与 H-1-MRI、CT 和 FDG-PET-CT 的融合对于所有患者都是可行的，并且显示出实体和坏死肿瘤区域的差异。平均肿瘤SI和肿瘤/CSF SI比率分别为13.3+/-1.8×103和0.83+/-0.14。在坏死肿瘤中，如中央非 FDG 活跃区域所示，平均肿瘤 SI 和肿瘤/CSF 比率分别为 19.4 x 103 和 1.10。 结论：Na-23-MRI 在肺癌患者中是可行的，并且可以提供有关肿瘤活力和潜在治疗反应的有价值的功能分子信息。
Purpose: Na-23-MRI has been proposed as a potential imaging biomarker for the assessment of tumor viability and the evaluation of therapy response but has not yet been evaluated in patients with lung cancer. We aimed to assess the feasibility of Na-23-MRI in patients with lung cancer.Materials and Methods: Three patients with stage IV adenocarcinoma of the lung were examined on a clinical 3 Tesla MRI system (Magnetom TimTrio, Siemens Healthcare, Erlangen, Germany). Feasibility of Na-23-MRI images was proven by comparison and fusion of Na-23-MRI with H-1-MR, CT and FDG-PET-CT images. Na-23 signal intensities (SI) of tumor and cerebrospinal fluid (CSF) of the spinal canal were measured and the SI ratio in tumor and CSF was calculated. One chemonaive patient was examined before and after the initiation of combination therapy (Carboplatin, Gemcitabin, Cetuximab).Results: All Na-23-MRI examinations were successfully completed and were of diagnostic quality. Fusion of Na-23-MRI images with H-1-MRI, CT and FDG-PET-CT was feasible in all patients and showed differences in solid and necrotic tumor areas. The mean tumor SI and the tumor/CSF SI ratio were 13.3 +/- 1.8 x 103 and 0.83 +/- 0.14, respectively. In necrotic tumors, as suggested by central non-FDG-avid areas, the mean tumor SI and the tumor/CSF ratio were 19.4 x 103 and 1.10, respectively.Conclusion: Na-23-MRI is feasible in patients with lung cancer and could provide valuable functional molecular information regarding tumor viability, and potentially treatment response.